Sophia Genetics Sa Stock News

BOSTON and LAUSANNE, Switzerland, March 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Executive Officer and Co-Founder Dr. Jur

BOSTON , LAUSANNE, Switzerland , and HIROSHIMA, Japan , Feb. 22, 2022 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH ), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan , to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan. With NGS for myeloid testing not widely available in Japan , a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms. Following the adoption of the SOPHiA DDM Platform, Masatoshi Nishizawa from Hiroshima University presented a research case study at the 83 rd Annual Meeting of Japanese Society of Hematology (Sendai, September 23-25, 2021 ).

BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for th

BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time.

BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the

SOPHiA Genetics SA (SOPH) shares closed today 19.7% lower than it did at the end of yesterday. The stock is currently up 0.2% year-to-date, down 15.7% over the past 12 months, and down 15.7% over the past five years. Today, the Dow Jones Industrial Average fell 1.5%, and the S&P 500 fell 1.8%. Trading Activity Shares traded as high as $15.83 and as low as $11.75 this week.Shares closed 42.7% below its 52-week high and 1.6% below its 52-week low.Trading volume this week was 71.0% higher than the 10-day average and 198.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -105.8% The company's stock price performance over the past 12 months lags the peer average by 44.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOPHiA Genetics SA (SOPH) shares closed 1.6% lower than its previous 52 week low, giving the company a market cap of $894M. The stock is currently up 0.2% year-to-date, down 15.7% over the past 12 months, and down 15.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 198.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -105.8% The company's stock price performance over the past 12 months lags the peer average by 44.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOPHiA Genetics SA (SOPH) shares closed this week 28.5% higher than it did at the end of last week. The stock is currently up 10.6% year-to-date, down 6.9% over the past 12 months, and down 6.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Shares traded as high as $15.83 and as low as $11.75 this week.Shares closed 28.6% below its 52-week high and 22.4% above its 52-week low.Trading volume this week was 277.6% higher than the 10-day average and 397.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.5% higher than its 5-day moving average, 6.2% higher than its 20-day moving average, and 6.0% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -361.5% The company's stock price performance over the past 12 months beats the peer average by -34.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOPHiA Genetics SA (SOPH) shares closed today 11.4% higher than it did at the end of yesterday. The stock is currently down 0.7% year-to-date, down 16.5% over the past 12 months, and down 16.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $15.60 and as low as $11.75 this week.Shares closed 21.2% below its 52-week high and 35.2% above its 52-week low.Trading volume this week was 20.8% higher than the 10-day average and 0.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -74.0% The company's stock price performance over the past 12 months lags the peer average by 70.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial O

BOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Off

Equities analysts predict that SOPHiA Genetics SA (NASDAQ:SOPH) will post $11.33 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for SOPHiA Genetics earnings, with estimates ranging from $11.26 million to $11.40 million. The firm is scheduled to announce its next earnings results on Wednesday, February 9th. On average, analysts []

SOPHiA Genetics SA (NASDAQ:SOPH) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 550,400 shares, an increase of 17.2% from the November 15th total of 469,700 shares. Approximately 1.1% of the shares of the stock are sold short. Based on [] The post SOPHiA Genetics SA (NASDAQ:SOPH) Short Interest Update appeared first on ETF Daily News .

Wall Street brokerages forecast that SOPHiA Genetics SA (NASDAQ:SOPH) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for SOPHiA Genetics earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.32). The firm is expected to report []

SOPHiA Genetics SA (NASDAQ:SOPH) shares fell 6.4% during trading on Friday . The company traded as low as $12.53 and last traded at $12.53. 230 shares were traded during mid-day trading, a decline of 100% from the average session volume of 95,414 shares. The stock had previously closed at $13.38. A number of research firms []